KRAS mutation in colon cancer: A marker of resistance to EGFR-I therapy

Annals of Surgical Oncology

Volumn 17, Issue 4, 2010, Pages 1168-1176

  Siddiqui, Ahmad D ^a   Piperdi, Bilal ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB;

CANCER RESISTANCE; CLINICAL ASSESSMENT; COLON CANCER; GENE MUTATION; GENETIC MARKER; HUMAN; MONOTHERAPY; ONCOGENE K RAS; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 77952092038     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0811-z     Document Type: Review

References (53)

1. American Cancer Society. Cancer facts and figures. http://www.cancer.org/ downloads/STT/2008CAFFfinalsecured.pdf. Accessed March 25, 2009.
2. ML Veronsese W Sun B Giantonio, et al. 2005 A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer Br J Cancer 92 1846 1849 10.1038/sj.bjc.6602569 (Pubitemid 40826131)
3. CA Townsley P Major LL Siu, et al. 2006 Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer Br J Cancer 94 1136 1143 10.1038/sj.bjc.6603055 1:CAS:528:DC%2BD28XjsFaksrk%3D 16570047
4. Erbitux (cetuximab) [prescribing information]. Branchburg, NJ: ImClone Systems Inc; revised November 2008.
5. Vectibix (panitumumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; revised February 2009.
6. D Cunningham Y Humblet S Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 10.1056/NEJMoa033025 1:CAS:528:DC%2BD2cXlvFGitbk%3D 15269313 (Pubitemid 38944402)
7. DJ Jonker CJ O'Callaghan CS Karapetis, et al. 2007 Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2040 2048 10.1056/NEJMoa071834 1:CAS:528:DC%2BD2sXhtlWis7rI 18003960 (Pubitemid 350106711)
8. E Van Cutsem M Peeters S Siena, et al. 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 1658 1664 10.1200/JCO.2006.08.1620 17470858 (Pubitemid 46797944)
9. EP Mitchell R Perez-Soler E Van Cutsem ME Lacouture 2007 Clinical presentation and pathophysiology of EGFRI dermatologic toxicities Oncology (Williston Park) 21 11 Suppl 5 4 9
10. S Tejpar H Piessevaux K Claes, et al. 2007 Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study Lancet Oncol 8 387 394 10.1016/S1470-2045(07)70108-0 1:CAS:528:DC%2BD2sXkslKru70%3D 17466895 (Pubitemid 46621761)
11. M Malumbres M Barbacid 2003 RAS oncogenes: The first 30 years Nat Rev Cancer 3 459 465 10.1038/nrc1097 1:CAS:528:DC%2BD3sXktFOnsbs%3D 12778136 (Pubitemid 37328850)
12. S Schubbert K Shannon G Bollag 2007 Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 295 308 10.1038/nrc2109 1:CAS:528:DC%2BD2sXjtlyhtLs%3D 17384584 (Pubitemid 46480970)
13. A Lievre JB Bachet D Le Corre, et al. 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992 3995 10.1158/0008-5472.CAN-06-0191 1:CAS:528:DC%2BD28XjsFSlsb0%3D 16618717
14. S Benvenuti A Sartore-Bianchi F Di Nicolantonio, et al. 2007 Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643 2648 10.1158/0008-5472.CAN-06-4158 1:CAS:528: DC%2BD2sXivV2ns7w%3D 17363584 (Pubitemid 46548951)
15. W De Roock H Piessevaux J De Schutter, et al. 2008 KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 508 515 10.1093/annonc/mdm496 17998284 (Pubitemid 351325672)
16. G Finocchiaro F Cappuzzo PA Janne, et al. 2007 EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer J Clin Oncol 25 168s
17. A Lievre JB Bachet V Boige, et al. 2008 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 374 379 10.1200/JCO.2007.12.5906 1:CAS:528: DC%2BD1cXitVGntLc%3D 18202412 (Pubitemid 351171687)
18. S Khambata-Ford CR Garrett NJ Meropol, et al. 2007 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 3230 3237 10.1200/JCO.2006.10.5437 1:CAS:528:DC%2BD2sXhtVWqs7rF 17664471 (Pubitemid 47325606)
19. DJ Freeman T Juan M Reiner, et al. 2008 Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone Clin Colorectal Cancer 7 184 190 10.3816/CCC.2008.n.024 1:CAS:528:DC%2BD1cXnvVCqt78%3D 18621636 (Pubitemid 351758148)
20. J Benhattar L Losi P Chaubert, et al. 1993 Prognostic significance of K-ras mutations in colorectal carcinoma Gastroenterology 104 1044 1048 1:STN:280:DyaK3s3hs1SisQ%3D%3D 8462792 (Pubitemid 23090756)
21. JC Lee ST Wang MD Lai, et al. 1996 K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers Anticancer Res 16 3839 3844 1:STN:280:DyaK2s7psVyhuw%3D%3D 9042267
22. MC Etienne-Grimaldi JL Formento M Francoual, et al. 2008 K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy Clin Cancer Res 14 4830 4835 10.1158/1078-0432.CCR-07- 4906 1:CAS:528:DC%2BD1cXpt1ejtbg%3D 18676755
23. CS Karapetis S Khambata-Ford DJ Jonker, et al. 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757 1765 10.1056/NEJMoa0804385 1:CAS:528:DC%2BD1cXht12nu77J 18946061
24. RG Amado M Wolf M Peeters, et al. 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626 1634 10.1200/JCO.2007.14.7116 1:CAS:528:DC%2BD1cXltlWhsrw%3D 18316791
25. AL Cohn DA Smith A Neubauer, et al. 2009 Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status J Clin Oncol 27 184s 10.1200/JCO.2008.16.6785
26. C Bokemeyer I Bondarenko A Makhson, et al. 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663 671 10.1200/JCO.2008.20.8397 1:CAS:528:DC%2BD1MXjsVCjsrk%3D 19114683
27. E Van Cutsem C-H Kohene E Hitre, et al. 2009 Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 1408 1417 10.1056/NEJMoa0805019 19339720
28. ER Fearon B Vogelstein 1990 A genetic model for colorectal tumorigenesis Cell 61 759 767 10.1016/0092-8674(90)90186-I 1:CAS:528:DyaK3cXktlyhtrg%3D 2188735 (Pubitemid 20185636)
29. B Vogelstein ER Fearon SR Hamilton, et al. 1988 Genetic alterations during colorectal-tumor development N Engl J Med 319 525 532 1:STN:280:DyaL1czgt1aqtQ%3D%3D 2841597
30. J Rak Y Mitsuhashi L Bayko, et al. 1995 Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis Cancer Res 55 4575 4580 1:CAS:528:DyaK2MXoslWms7Y%3D 7553632
31. M Esteller S Gonzalez RA Risques, et al. 2001 K-ras and p16 aberrations confer poor prognosis in human colorectal cancer J Clin Oncol 19 299 304 1:CAS:528:DC%2BD3MXhtVektro%3D 11208819 (Pubitemid 32112840)
32. JL Westra M Schaapveld H Hollema, et al. 2005 Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients J Clin Oncol 23 5635 5643 10.1200/JCO.2005.04.096 1:CAS:528: DC%2BD2MXhtVersrzN 16110022 (Pubitemid 46300159)
33. WS Samowitz JA Holden K Curtin, et al. 2001 Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer Am J Pathol 158 1517 1524 1:CAS:528:DC%2BD3MXjtVWht7o%3D 11290569 (Pubitemid 32281315)
34. Juan T, Suggs S, Wolf M, et al. A comparability study of 4 commercial KRAS tests (abstract 1811). Paper presented at: 99th AACR Annual Meeting; 2008; San Diego, CA.
35. CJ Allegra JM Jessup MR Sommerfield, et al. 2009 American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2091 2096 10.1200/JCO.2009.21.9170 19188670
36. JH van Krieken A Jung T Kirchner, et al. 2009 KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: Proposal for an European quality assurance program Virchows Arch 453 417 431 10.1007/s00428-008-0665-y
37. DJ Ahnen P Feigl G Quan, et al. 1998 Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study Cancer Res 58 1149 1158 1:CAS:528:DyaK1cXhvV2rsro%3D 9515799 (Pubitemid 28183202)
38. A Russo V Bazan V Agnese, et al. 2005 Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies Ann Oncol 16 Suppl 4 iv44 iv49 10.1093/annonc/mdi907 15923428 (Pubitemid 43084945)
39. H Bouzourene P Gervaz JP Cerottini, et al. 2000 p53 and K-ras as prognostic factors for Dukes' stage B colorectal cancer Eur J Cancer 36 1008 1015 10.1016/S0959-8049(00)00036-8 1:CAS:528:DC%2BD3cXjsVCqsLk%3D 10885605 (Pubitemid 30316426)
40. HI Hurwitz J Yi W Ince, et al. 2009 The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer Oncologist 14 22 28 10.1634/ theoncologist.2008-0213 1:CAS:528:DC%2BD1MXjt1Clt7o%3D 19144677
41. EP Mitchell M LaCouture H Shearer, et al. 2009 Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC) J Clin Oncol 27 805s 10.1200/JCO.2008.17.0910
42. Folprecht G, Gruenberger T, Hartmann JT, et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM-study). Paper presented at: 2009 Gastrointestinal Cancers Symposium; January 15-17, 2009; San Francisco, CA.
43. S Siena J Tabernero RL Burkes, et al. 2008 Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data J Clin Oncol 26 186s
44. M Peeters G Wilson M Ducreux, et al. 2008 Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results J Clin Oncol 26 194s
45. JR Hecht E Mitchell T Chidiac, et al. 2009 A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 672 680 10.1200/JCO.2008.19.8135 1:CAS:528:DC%2BD1MXjsVCjs74%3D 19114685
46. J Tol M Koopman A Cats, et al. 2009 Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 563 572 10.1056/NEJMoa0808268 1:CAS:528:DC%2BD1MXhsFyitrw%3D 19196673
47. A phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/ leucovorin with bevacizumab, or cetuximab (C225), or with the combination or bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum. http://www.clinicaltrials.gov/ct2/show/NCT00265850. Accessed April 18, 2009.
48. SPIRITT-Q2W FOLFIRI regimen plus panitumumab or a Q2W FOLFIRI regimen plus bevacizumab for 2nd-line mCRC. http://www.clinicaltrials.gov/ct2/show/ NCT00418938. Accessed April 18, 2009.
49. F Loupakis A Ruzzo C Cremolini, et al. 2009 KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 101 715 721 10.1038/sj.bjc.6605177 1:CAS:528:DC%2BD1MXpvFyisb0%3D 19603018
50. A Sartore-Bianchi M Martini F Molinari, et al. 2009 PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 7 1857 10.1158/0008-5472.CAN-08-2466
51. F Di Nicolantonio M Martini F Molinari, et al. 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705 5712 10.1200/JCO.2008.18.0786 1:CAS:528: DC%2BD1MXotFemsA%3D%3D 19001320
52. H Prenen J De Schutter B Jacobs, et al. 2009 PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer Clin Cancer Res 15 3184 3188 10.1158/1078-0432.CCR-08-2961 1:CAS:528:DC%2BD1MXltFOrur0%3D 19366826
53. DJ Jonker C Karapetis C Harbison 2009 et al. High epiregulin (EREG) plus K-ras (WT) status as predictors of cetuximab benefit in the treatments of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-a phase III trial of cetuximab versus best supportive care (BSC) J Clin Oncol 27 172s